Lyra Therapeutics Inc (LYRA NASDAQ) stock market data APIs
$3.9867
0.18(4.5%)
as of December 8, 2025
Try our APIs with
free plan!
Lyra Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Prev. Close
3.9867
Open
4.1712
High
4.2329
Low
3.8388
52 wk Range
2.84-34
Market Cap
7 046 K
Shares Outstanding
1 775 K
Revenue
600 K
EPS
-3.38
Beta
-0.013
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Lyra Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lyra Therapeutics Inc data using free add-ons & libraries
Get Lyra Therapeutics Inc Fundamental Data
Lyra Therapeutics Inc Fundamental data includes:
- Net Revenue: 600 K
- EBITDA: -31 898 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.185
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lyra Therapeutics Inc News
New
Lyra Therapeutics GAAP EPS of -$3.38 beats by $0.98
* Lyra Therapeutics press release [https://seekingalpha.com/pr/20304976-lyra-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (LYRA [https://seekingalpha.com/s...
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 20...
Dentsply International (XRAY) Lags Q3 Earnings Estimates
Dentsply International (XRAY) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.5 per share a year ago. Thes...
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
